Dr. Youling Gong 宫友陵
Chief Physician, Associate Professor
Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical and radiation therapy, small-molecule targeted drugs, and immunotherapy for thoracic malignancies, including lung cancer, esophageal cancer, and mediastinal malignant tumors.
Dr. Gong holds a PhD in Oncology from Sichuan University. Since graduation, Dr. Gong has worked at West China Hospital Cancer Center and the State Key Laboratory of Biotherapy. From 2003 to 2005, Dr. Gong conducted NIH-funded research in tumor molecular biology and molecular epidemiology at the University of South Carolina. Dr. Gong is a member of the International Association for the Study of Lung Cancer.
Professional roles
- Vice Chair, Youth Committee of Radiation Oncology, Sichuan Province
- Standing Committee Member, Tumor Rehabilitation Committee, Geriatrics Professional Committee, Sichuan Province
- Deputy Leader, Radiation Oncology Biology Group, Sichuan Province
- Secretary, Radiation Oncology Professional Committee, Sichuan Province
Name order: in Chinese the family name comes first (Gong Youling). Papers usually list the name as Youling Gong or Gong Y.
Selected publications
107 papers on PubMed matched by name and affiliation; 23 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancers (Basel), 2025 (senior author): Impact of Response Assessment Intervals on Survival and Economic Burden in Long-Term Responders to Immunotherapy for Advanced Non-Small-Cell Lung Cancer. PubMed 41154368
- BMC Cancer, 2025 (senior author): Development and validation of a dynamic nomogram for predicting brain metastasis in stage III NSCLC patients undergoing definitive chemoradiotherapy. PubMed 41039258
- Oncologist, 2025 (senior author): Multimodal rehabilitation to improve quality of life and fatigue after radiotherapy in esophageal cancer patients: a randomized trial. PubMed 40542586
- Am J Surg, 2025 (senior author): Surgery/non-surgery-based strategies for invasive locally-advanced non-small cell lung cancer in the era of precision medicine. PubMed 39667297
- Invest New Drugs, 2024 (senior author): First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?. PubMed 38386170
- Front Oncol, 2023 (senior author): Involved-field irradiation or elective-nodal irradiation in neoadjuvant chemo-radiotherapy for locally-advanced esophageal cancer: comprehensive analysis for dosimetry, treatment-related complications, impact on lymphocyte, patterns of failure and survival. PubMed 37886166
- Br J Radiol, 2023 (senior author): The quality and clinical translation of radiomics studies based on MRI for predicting Ki-67 levels in patients with breast cancer. PubMed 37724784
- Thorac Cancer, 2023 (senior author): Pericardial irradiation dose may be strongly associated with grade 4 lymphopenia and affect prognosis in patients with locally advanced esophageal cancer receiving definitive concurrent chemoradiotherapy. PubMed 37519061
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion